Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
The first sublingual therapy for the intermittent treatment of uncontrolled OFF episodes for adult people living with Parkinson’s Disease ...
The term best semaglutide for weight loss in 2026 reflects growing consumer interest in medically supervised GLP-1 weight loss programs. As demand for effective and regulated weight management ...
Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...
This important study introduces a new biology-informed strategy for deep learning models aiming to predict mutational effects in antibody sequences. It provides solid evidence that separating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback